Evotec SE (EVO) Cash from Financing Activities (2009 - 2026)
Evotec SE's (EVO) quarterly Cash from Financing Activities came in at -$22.3 million in Q1 2026, down 159.97% year-over-year from $37.3 million in Q1 2025, and down 192.61% quarter-over-quarter from $24.1 million in Q4 2025.
Analysis
Evotec SE (EVO) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Evotec SE has disclosed Cash from Financing Activities across 9 years of filings, most recently posting -$22.3 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 159.97% year-over-year to -$22.3 million; the TTM figure through Mar 2026 stood at -$29.0 million (up 77.69% YoY), while the FY2025 annual figure was -$42.5 million, up 75.67% from the prior year.
- Cash from Financing Activities came in at -$22.3 million for Q1 2026 at Evotec SE, down from $24.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $37.3 million in Q1 2025 to a low of -$128.2 million in Q2 2024.
- Average Cash from Financing Activities over 5 years is -$11.9 million, with a median of -$7.1 million recorded in 2022.
- Year-over-year, Cash from Financing Activities plunged 1780.81% in 2024 and surged 684.31% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$7.8 million in 2022, then surged by 416.81% to $24.9 million in 2023, then tumbled by 226.06% to -$31.3 million in 2024, then soared by 177.01% to $24.1 million in 2025, then sank by 192.61% to -$22.3 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$22.3 million in Q1 2026, $24.1 million in Q4 2025, and -$14.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | -214.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | -288.34 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | -8.12 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | -164.66 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 16.49 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 33,000.00 |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | 248,151.59 |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | -118,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -22.35 Mn |
| Dec 31, 2025 | 24.13 Mn |
| Sep 30, 2025 | -14.19 Mn |
| Jun 30, 2025 | -16.64 Mn |
| Mar 31, 2025 | 37.27 Mn |
| Dec 31, 2024 | -31.34 Mn |
| Sep 30, 2024 | -7.89 Mn |
| Jun 30, 2024 | -128.19 Mn |
| Mar 31, 2024 | -6.38 Mn |
| Dec 31, 2023 | 24.86 Mn |
| Jun 30, 2023 | 7.63 Mn |
| Mar 31, 2023 | 3.73 Mn |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | -4.69 Mn |
| Jun 30, 2022 | -43.24 Mn |
| Mar 31, 2022 | -5.92 Mn |
| Dec 31, 2021 | 441.41 Mn |
| Sep 30, 2021 | -6.26 Mn |
| Jun 30, 2021 | -6.59 Mn |
| Mar 31, 2021 | 21.63 Mn |